Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...

Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...

Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement ...

Inc. (GILD) for example. In the following article, I will look at Johnson & Johnson again and try to answer the question if the stock is still a “Buy” at this point. On October 15, 2024 ...

U.S. stocks were rising across the board on Wednesday morning, buoyed by the advance in megacap technology names. Under the surface, however, there is furious paddling. The Dow Jones Industrial ...

Magic Johnson is now worth an estimated $1.2 billion. His career earnings as a basketball player was $40 million. The magic? He says it comes from—of course—teaming up.

Johnson & Johnson (NYSE: JNJ) stock is up 1.8% in the five days after the company announced its $14.6 billion acquisition of ...

s disease-related psychosis and agitation Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which ...